<DOC>
	<DOCNO>NCT01931306</DOCNO>
	<brief_summary>To provide expanded access evaluate safety , tolerability efficacy afatinib patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) harbor Epidermal Growth Factor Receptor ( EGFR ) mutation ( ) never treat EGFR tyrosine kinase inhibitor ( TKI )</brief_summary>
	<brief_title>Expanded Access Study Afatinib Treatment-naive Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1. locally advanced metastatic NonSmall Cell Lung Cancer 2 . Epidermal Growth Factor Receptor mutation positive result per institution 's test methodology . Any type EGFR mutation allow 3 . Treatment na√Øve patient receive one line chemotherapy , chemotherapy include neo adjuvant adjuvant chemotherapy within 1 year enrolment 4. male female patient age 18 year 5 . Adequate organ function , define follow : 1 . Absolute Neutrophil Count 1500 per mm3 . ANC 1000 per mm3 may consider special circumstance benign cyclical neutropenia judge investigator discussion sponsor . 2 . Platelet count 75,000 per mm3 3 . Serum creatinine 1.5 time upper limit normal 4 . Total Bilirubin 1.5 time upper limit institutional normal . Patients Gilbert 's syndrome total bilirubin must 4 time institutional upper limit normal . 5 . Aspartate Amino Transferase Alanine Amino Transferase three time upper limit normal , related liver metastases five time ULN . 6 . ECOG score 0 2 7. write informed consent patient guardian prior admission trial consistent International Conference Harmonisation Good Clinical Practice guideline local law . Exclusion criterion : 1. prior treatment EGFR tyrosine kinase inhibitor 2. hormonal anticancer treatment within 2 week prior start trial treatment , continue use anti androgen gonadorelin analogue treatment prostate cancer permit 3. radiotherapy within 14 day prior drug administration , except follow : 1 . Palliative radiation organ chest may allow 2 week prior drug administration , 2 . Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol . 4. major surgery within 4 week start trial treatment schedule surgery project course trial 5. know hypersensitivity afatinib excipients 6. history presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association classification 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior start trial treatment . 7 . Women ChildBearing Potential men able father child , unwilling use adequate contraception prior trial entry , duration trial participation least 2 week treatment end . 8. childbearing potential : 1. nurse 2. pregnant 3. use acceptable method birth control , plan continue use method throughout trial , agree submit pregnancy test require protocol 9. history concomitant condition , opinion investigator , would compromise patient 's ability comply trial interfere evaluation safety trial drug 10. previous concomitant malignancy sit , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure . 11. require treatment prohibit concomitant medication stop duration trial participation 12. know preexist interstitial lung disease 13. presence poorly control gastrointestinal disorder could affect absorption trial drug 14. active hepatitis B infection , active Hepatitis C infection 15. meningeal carcinomatosis 16. symptomatic brain metastasis , patient asymptomatic brain metastasis , previously treat , eligible provide Stable Disease least 4 week stable dos medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>